humans (Bjorkman et al., 1987a,b; Garrett et al., 1989; Saper et al., 1991; Madden et al., 1991 Madden et al., ,1992 Madden et al., ,1993 Silver et al., Molecules of the major histocompatibility complex (MHC) 1992; Collins et al., 1994; Simth et al., 1996a,b) . Detailed bind and present short antigenic peptide fragments on the comparisons of the MHC-peptide complexes (Guo et al., surface of a cell for surveillance by T-cell receptors (TCRs).
1993; Young et al., 1995; Madden, 1995;  Chelvanayagam Recognition between the TCR and the MHC-peptide complex et al., 1996) revealed a number of striking similarities. Firstly, mediates the destruction of the antigen presenting cell (Townpeptides appeared to be anchored in the cleft by 'specificity' send and Bodmer, 1989) . In the normal scheme of things, pockets (Garrett et al., 1989; Saper et al., 1991) . The polypeptide fragments derived from 'foreign' proteins are recogmorphism between different allelic products leads to variation nized by TCRs, while peptide fragments derived from 'self' mostly in the amino acids that line the cleft, changing the proteins do not generally activate T-cells. There are two classes shape and thus specificity of the pockets (Matsumura et al., of MHC that present peptides. Class I molecules present 1992) . Thus, different MHC molecules are able to bind different peptide fragments from endogenous sources, such as viruses, peptide repertoires. This paralleled the results of peptide elution while Class II molecules present peptide fragments from and pool sequencing studies, where it was found that MHC exogenous agents that have infected the cell. These molecules molecules have a specific preference for the type of amino have attracted much attention for a number of reasons including acid that occurs at different positions along the peptide (Falk their usefulness in tissue matching for transplantation, their et al., 1991; Jardetsky et al., 1991; Hunt et al., 1992) . The high polymorphic allelism (Klein and Figueroa, 1986) , their 'anchor' residues delineated by these studies fit into the strong association with disease susceptibility (Owerbach and 'pockets' found in the crystal structures. Another remarkable Gabbay, 1996) and because of the clues that they leave as to finding was that the mode of peptide binding appeared to be the evolution and migrational patterns of humans (Parham and canonical. Irrespective of whether the peptide was eight, nine Ohta, 1996) and other species. The recently solved structure or ten amino acids in length, the main chain conformation at of the MHC-peptide-TCR complex is shown in Figure 1 . the ends of the peptide are essentially the same in all of the Since the discovery of MHC restriction, that T-cells detect complexes solved to date. Conserved amino acids at the ends infected cells by identifying peptide antigens complexed with of the cleft (Y7, Y84, T143, W147, Y159, Y171) serve to specific MHC molecules (Zinkernagel and Doherty, 1974) , stabilize the peptide by forming hydrogen bonds to the backinitial progress towards an understanding of the molecular bone of the peptide. In this way, the amino acids along the basis of this process was painstaking and slow. The first peptide are free to vary and complement the pocket specificity structural milestone came with the solution of the extracellular of the particular MHC molecule. Further, the central portion domains of the first MHC structure: the human Class I HLAof the peptide bulges up and out of the cleft. Subtle differences A*0201 (Bjorkman et al., 1987a) . The structure consists of in the MHC-peptide hydrogen bonding have been observed. three covalently-linked domains the first two of which (α1 These can arise, for example, by small shifts in the positions and α2) each comprise a long, irregular helix packed against of the α1 and α2 helices (Guo et al., 1993; , a four-stranded antiparallel sheet. These domains associate to 1996b) but most strikingly as a consequence of bound water form a single eight-stranded antiparallel sheet above which structure (Smith et al., 1996a,b) . The latter studies highlight the α1 and α2 helices lie antiparallel to one another. Beneath the important mediating role played by solvent in the binding the sheet 'floor', the third domain (α3) adopts an immunoglobcleft. Nonetheless, the general 'rules' for peptide binding to ulin type fold that interacts with other molecules such as CD8.
MHC molecules appear to be adhered to, even when additional Parts of both the α3 domain and the under side of the sheet residues occur at the end of the peptide and protrude from the floor form the interface for β2 microglobulin which binds nonend of the cleft (Collins et al., 1994) . covalently with MHC in the mature complex. It was speculated
The first Class II structure to be solved, HLA-DR1 (Brown that the cleft formed between the α1 and α2 helices might be et al., 1993), was able to ratify a theoretical prediction for the where the peptide fragments were bound (Bjorkman et al., overall fold of the molecule, based on similarities to the Class 1987b) and indeed this turned out to be the case. Subsequent I amino acid sequence, domain and gene organization (Brown crystallographic studies on Class I molecules added more et al., 1988) . Although Class II molecules consist of two to the emerging picture of how peptides were bound and separate chains, α and β, each consisting of a Class I α1-like presented.
Structural superposition and comparison of related molecules domain covalently linked to a Class I α3-like domain, the et al., 1996) prepared with MOLSCRIPT (Kraulis, 1991) . The peptide is shown in a balland-stick representation in the antigen binding cleft, above which are the TCR domains.
overall appearance of the molecule is very similar to that of et al., 1996) . In this model, the superantigen acts as a wedge between the MHC and TCR, thereby preventing normal the Class I-β2 microglobulin complex. A key difference is in the antigen binding groove. Whereas in the Class I molecules engagement of the MHC-peptide-TCR complex. The first crystal structures for the Vα (Fields et al., 1995 ) the ends of the groove are closed off, in the Class II molecule they are open and allow longer peptides to bind. The HLAand separately the Vβ chain (Bently et al., 1995) of the α/β TCR signalled that yet another MHC milestone was on the DR1 structure in complex with an influenza virus peptide showed that in contrast to Class I structures, horizon and, within a short time, the solution of the Class I MHC-peptide-TCR trimolecular complex 'of mice (Garcia the peptide binds in the cleft as a straight extended chain with a strong twist. The structure of HLA-DR3 complexed with the et al., 1996) and men (Garbocezi et al., 1996) ' was revealed. The structures were similar and showed that the TCR is oriented CLIP peptide (Ghosh et al., 1995) and the recent structure for the mouse I-E k in complex with two antigenic peptides diagonally across the upper face of the MHC, interacting with the C-terminal ends of both helices. The CDR3 loops engage (Fremont et al., 1996) revealed that the peptide conformations were very similar to that of the influenza virus peptide in the central residues of the peptide that bulge out of the cleft. The CDRα1 and CDRβ1 loops interact with the N-and Ccomplex with HLA-DR1.
This also appears to be the case for a mixture of endogenous terminal ends of the peptide, respectively. The CDR2 loops lie over the helices with CDRα2 above the α2 domain helix peptides bound with a DR1-superantigen complex, leading to the suggestion that peptides binding to Class II molecules and CDRβ2 above the α1 domain helix. Predictions for the interaction of these loops with the MHC-peptide complex are adopt a canonical (polyprolein type II) conformation (Jardetzky et al., 1996) . Superantigens are viral or bacterial proteins that largely correct (Chothia et al., 1988; Davis and Bjorkman, 1988; Claverie et al., 1989) . However, predictions for the TCR bind to MHC and TCR molecules and stimulate a large numbers of T-cells. These molecules have been implicated in orientation (Chothia et al., 1988; Davis and Bjorkman, 1988; Vasmatzis et al., 1996) were not so successful, but at least many diseases including toxic shock and food poisoning. The mechanism by which this occurs is still unclear but the one model (Sun et al., 1995) was correct. Although, no structure has been solved for a Class II MHC-peptide TCR structures of a TCR-superantigen complex (Fields et al., 1996) , the DR1-superantigen complex and a complex, it has been suggested (Garbocezi et al., 1996) that α/β TCRs may well interact with Class II molecules in the Vα homodimer (Fields et al., 1995) have been used to propose a model for the MHC-superantigen-TCR complex (Fields same manner as with Class I, given that the canonical peptide conformations of both Class I and II molecules project residues peptide complex, it is more difficult for an antibody to recognize just residues on the peptide since, in the canonical out of the binding clefts in approximately the same positions.
Armed with this structural knowledge, researchers have mode of binding, the majority of the peptide is buried in the cleft. The binding of such antibodies to the MHC-peptide been able to employ protein engineering techniques to improve models for the study of human diseases. For example, the α1 complex suggests that much more of the peptide is available for antibody recognition. Thus, while accurate modelling for and α2 domains of human HLA-A*0201 have been 'grafted' onto the α3, transmembrane and cytosolic domains of mouse some MHC-peptide complexes should be possible, for others, more structural data may still be necessary. H-2K b (Vitiello et al., 1991) . This transgenic mouse presents a useful means to test peptide binding specificities for the
The crystal structures of MHC molecules and their complexes with peptides, superantigens and TCRs have contributed human molecule. The constraints in peptide binding in Class I and II molecules have also opened the door for theoretical enormously to our appreciation of the molecular basis for cellular immunity. While structural evidence for novel binding techniques. Predictions for peptide binding repertoires of given MHC molecules have begun (Rognan et al., 1994; Lim et al., modes for peptides in Class I and II clefts would herald yet another structural milestone towards our full understanding of 1996; Sezerman et al., 1996) . Homology modelling has been widely used to explain observed experimental results such as MHC, there are many other challenges that also remain to be elucidated. The role of lectins and carbohydrates in MHC differences in peptide binding of different allelic products. In fact, given the overall similarity in the structure of different recognition by natural killer (NK) cells (Parham, 1996) is just one example. Nonetheless, the past research achievements Class I or Class II MHC molecules, coupled with the canonical binding modes of peptides, it might be expected that fully summarized above provides the motivation and enthusiasm to strive towards the milestones that lie ahead. automating such a modelling process is straightforward. It turns out that this is not the case. The difficulties introduced by solvent, the flexibility of the central portion of the peptideMHC molecule and the stability it can provide to the MHC- Engng, 9, 1151 Engng, 9, -1164 peptide complex as a whole has been suggested (Freemont Chen,W., Khilko,S., Fecondo,J., Margulies,D.H. and McCluskey,J. (1994) J. et al., 1995) since it was found that the peptide SRDHSRTPM, Exp. Med., 180, 1471 -1483 . Chothia,C., Boswell,D.R. and Lesk,A.M. (1988 lacking the anchor motif, still had a high affinity for but Claverie,J.M., Prochnicka-Chalufour,A. Bougueleret,L. (1989) Immunol. provided little thermal stability to H-2K b . Formylated peptides Today, 10, [10] [11] do not bind canonically to the mouse H2-M3 MHC molecule Collins,E.J., Garboczi,D.N. and Wiley,D.C. (1994) Nature, 371, 626-629. (Wang et al., 1995) . Daser,A., Urlaub,H. and Henklein,P. (1994) Reports of overlapping peptides binding to MHC and Falk,K., Rötzschke,O., Stevanović,S., Jung,G. and Rammensee,H.-G. (1991) inducing cell lysis are also cause for concern (Daser et al., Nature, 351, 290-296. 1994 ). While it could be that the amino acid sequence in such expected H-2K b motif. One explanation for this is that these (1992) Science, 257, 919-926. Fremont,D.H., Stura,E.A., Matsumura,M., Peterson,P.A. and Wilson,I. (1995) peptides may be able to bind transiently in the cleft. Being
Proc. Natl Acad. Sci. USA, 92, 2479 USA, 92, -2483 anchored by one or more residues, not necessarily at expected then be sufficient to pin such a peptide in place. A line of (1996) Nature, 384, 134-141. evidence supporting this is that antibodies have been raised Garcia,K.C., Degano,M., Stanfield,R.L., Brunmark,A., Jackson,M.R., that can recognize the peptide in an MHC-peptide complex Peterson,P.A., Teyton,L. and Wilson,I.A. (1996) Science, 274, 209-219. ( Apostolopoulos et al., submitted) . While the immunoglobulinGarrett,T.P., Saper,M.A., Bjorkman,P.J., Strominger,J.L. and Wiley,D.C. (1989) Nature, 342, 692-696.
like folds of the α and β chains of the TCR bind the MHC-
